A Transformative Vision As the leader of the type 1 diabetes community, JDRF unifies global efforts to cure, treat, and prevent T1D. JDRF is committed, as we always have been, to delivering a cure for type 1 diabetes and its complications through the support of research. We are also focused on developing better treatments that transform the way people with T1D treat the disease today in order to help them live healthier lives now and in the future. Finally, JDRF focuses on prevention to keep future generations from getting T1D. Guided by our vision of cure, treat, and prevent, JDRF-funded research encompasses T1D at every life-stage: stopping or slowing its progression in people who are newly diagnosed; preversing it in those who have lived with the disease for years; avoiding or reversing complications; and preventing the disease in people at risk and in future generations. In addition to our research funding and leadership, JDRF’s advocacy efforts help support a variety of issues that are critical to JDRF achieving its research objectives. Our focus includes increased government funding for T1D research and a regulatory environment that allows people with T1D to benefit from potential new therapies and devices as quickly and safely as possible. Finally, JDRF’s outreach efforts provide practical support and resources for people with type 1 diabetes and their families every step of the way as they live with T1D. JDRF’s Research Goals: JDRF research is committed to improving the lives of every person with T1D and to curing this disease. JDRF’s research goals are realized by the projects being supported in three basic areas: CURE Restoring a person’s insulin-producing capability and halting or reversing the body’s misguided immune attack on the pancreas. TREAT Developing new devices and therapies that optimize blood sugar control and treat or prevent the complications of T1D. PREVENT Preventing T1D from occurring or stopping the disease process before it damages the pancreas. 2012 JDRF Research Funding Cure Research - $65.1 million Beta Cell Health & Regeneration Therapies - $23.9 million Immune Therapies- $6.8 million Beta Cell Encapsulation Therapies - $10.4 million Cure Biomarkers and Imaging Tools - $17.2 million Cure Transportfolio Projects - $6.8 million Treat Research - $35.7 million Artificial Pancreas Systems - $12.4 million Glucose-Control Therapies - $2.5 million Complications Prevention and Treatment Therapies - $20.8 million Prevention Therapies Research - $8.2 million General Research Projects - $1 million TOTAL 2012 RESEARCH FUNDING - $110 million JDRF Research Funding Overview  JDRF provided more than $110 million for T1D research in 2012, and currently has research projects in 17 countries, totaling $530 million. Since its founding in 1970, JDRF has funded more than $1.7 billion in diabetes research and has dramatically advanced the T1D scientific frontier and the management of this disease. More than 80 percent of JDRF’s expenditures directly support research and research-related education. JDRF maintains one of the best records among nonprofits of using supporters’ contributions effectively. In 2012, JDRF supported more than 50 clinical studies, evaluating new therapies and treatments for T1D and seeking to better understand the disease’s cause and progression. This growing emphasis on clinical trials testifies to JDRF’s commitment to moving beyond scientific discovery to delivering solutions to better treat and cure T1D. Locally, JDRF is currently funding multi-year, multi-million dollar research projects at the Benaroya Research Institute at Virginia Mason, University of Washington, and the UW Institute for Systems Biology. For more information, www.jdrf.org.